Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19

A neutrophil activation signature predicts critical illness and mortality in COVID-19

(2021) Matthew L. Meizlish et al.   Blood Advances

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

(2020) Giacomo Grasselli et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal

(2020) Hasan K. Siddiqi et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Cytokine storm and leukocyte changes in mild versus severe SARS‐CoV‐2 infection: Review of 3939 COVID‐19 patients in China and emerging pathogenesis and therapy concepts

(2020) Jin Wang et al.   JOURNAL OF LEUKOCYTE BIOLOGY

An inflammatory cytokine signature predicts COVID-19 severity and survival

(2020) Diane Marie Del Valle et al.   NATURE MEDICINE

Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19

(2020) Enrico Brunetta et al.   NATURE IMMUNOLOGY

Pentraxin 3: Potential prognostic role in SARS-CoV-2 patients admitted to the emergency department

(2020) Annalisa Schirinzi et al.   JOURNAL OF INFECTION

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

(2014) Frits van Rhee et al.   LANCET ONCOLOGY